Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026

In a post hoc analysis of 106 ESSENCE participants with MASH, liver scarring and BMI below 27 kg/m², semaglutide 2.4 mg once weekly favored placebo on several measures at week 72. Estimated treatment ratios were 0.61 for ALT, 0.67 for AST and 0.82 for PRO-C3; ELF score treatment difference was -0.45. The exploratory findings supplement previously reported histologic results, but the VCTE-LSM confidence interval included 1.0, and the analysis is hypothesis-generating.

Analysis

The incremental value is market reach, not a new efficacy proof: evidence in leaner patients could widen the pool clinicians consider for semaglutide, but it does not establish how many will be diagnosed, covered, or treated. Because the indication already has accelerated approval, this post hoc analysis is unlikely on its own to change near-term NVO earnings expectations. Its 106-person subgroup and biomarker-heavy readout limit the commercial signal; notably, the VCTE-LSM confidence interval includes no effect. The key economic bridge is whether the subgroup’s biopsy-based findings translate into durable clinical benefit and prescribing without unacceptable weight loss or tolerability trade-offs in patients with lower BMI.

Near term, treat as supportive sentiment rather than a fresh catalyst. Over 1–3 months, watch for independent scrutiny of the full subgroup histology and any evidence of payer access or prescribing beyond patients with obesity. Over 6–18 months, broader use could expand GLP-1 demand in MASH, while competing treatment approaches such as Madrigal Pharmaceuticals’ resmetirom may be more attractive for patients or clinicians seeking a non-GLP-1 option. Do not infer share loss or comparative efficacy from this analysis. The central reversal risk is failure to verify clinical benefit in the ongoing outcomes trial; biomarker improvements alone may not sustain broad adoption.

Key Decisions for Investors

• NVO: no event-driven position change on this release alone; retain existing exposure, but do not chase a headline-driven move. The subgroup result is directionally supportive, not a demonstrated near-term earnings revision.
• Watch for confirmatory evidence that the leaner subgroup’s histologic response is durable and translates to clinical outcomes. Failure to verify benefit in the ongoing trial would weaken the MASH expansion thesis and the basis for accelerated approval.
• Track uptake and access by BMI, plus discontinuation and tolerability in lower-BMI patients. Broader prescribing without a tolerability penalty would support the commercial case; limited coverage or weight-loss concerns would falsify the reach-expansion thesis.
• Avoid a relative-value short against other MASH approaches based on this release: it provides no head-to-head evidence. Reassess only when comparative outcomes, access, or prescribing data clarify which patient groups favor each treatment.